fidaxomicin

Details

Generic Name:
fidaxomicin
Project Status:
Withdrawn
Therapeutic Area:
Clostridium difficile infection
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dificid
Project Line:
Reimbursement Review
Project Number:
SF0847-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Request for Advice
Fee Schedule:
N/A
Indications:
​Clostridium difficile infection.
Recommendation Type:
N/A
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open05-Feb-24
Request for Advice received29-Jan-24
Manufacturer informed of request for advice31-Jan-24
Manufacturer information or comments due14-Feb-24
Request for Advice initiated15-Feb-24
Call for patient/clinician input closed02-Apr-24
Clarification:

- Patient input submission received from the Gastrointestinal Society

Draft CADTH review report(s) sent to sponsor16-Apr-24
Deadline for sponsors comments25-Apr-24
Expert committee meeting (initial)26-Jun-24
Clarification:

Project was withdrawn without issuing a revised recommendation